News from shionogi inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 03, 2015, 08:03 ET
Shionogi Inc. Logo

Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of...

May 19, 2015, 09:34 ET
Shionogi Inc. Logo

Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation

 Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant...

Mar 30, 2015, 02:00 ET
Shionogi & Co., Ltd. logo

Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation

 Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met...

Oct 09, 2014, 14:00 ET

Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens

S-649266, an investigational parenteral siderophore cephalosporin, exhibits marked potency against Gram-negative bacteria, including...

Oct 01, 2014, 09:00 ET
Shionogi Inc. Logo (PRNewsFoto/Shionogi Inc.)

Shionogi Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC

Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from...

Sep 08, 2014, 11:42 ET

Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens

 Findings reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) showed Shionogi's novel parenteral...

Sep 04, 2014, 09:00 ET
Shionogi Inc. Pledges to "Take Charge" in Honor of Menopause Awareness Month. Visit Today & Take The Pledge! (PRNewsFoto/Shionogi Inc.)

Shionogi Inc. Pledges to "Take Charge" in Honor of Menopause Awareness Month

This September, Shionogi Inc. supports the Women's Health Foundation with a five dollar donation for every pledge taken on

Jul 03, 2014, 09:00 ET

It's Time to Talk about Sex After Menopause, A New Campaign To Free Women From The Silence Around An Often-Neglected Area Of Women's Health

 Beginning July 4th, women, men and health care providers are encouraged to lend their social voices to an often-neglected area of women's...

Jan 13, 2014, 09:00 ET

Shionogi Inc. Announces Co-Promotion Agreement with Noven Pharmaceuticals For Brisdelle™ (Paroxetine) Capsules

 Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote...

Jun 25, 2013, 06:30 ET

Actress Virginia Madsen Partners With Shionogi Inc. To Empower Postmenopausal Women To Break The Silence Around Painful Intercourse Due To Menopause

Academy Award-nominated actress Virginia Madsen is never one to shy away from a conversation, even if the topic at first blush seems awkward or...

May 16, 2013, 11:03 ET

New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy

 A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of...

Feb 26, 2013, 15:10 ET

Shionogi Receives FDA Approval For Osphena™ (Ospemifene) For The Treatment Of Dyspareunia, A Symptom Of Vulvar And Vaginal Atrophy (VVA), Due To Menopause

 Shionogi Inc., the United States (U.S.)-based company of Shionogi & Co., Ltd., today announced that the U.S. Food and Drug Administration...

Jul 26, 2012, 16:30 ET

Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced 48-week data from the SPRING-2 Phase III study, which is evaluating the investigational integrase...

Jul 11, 2012, 02:08 ET

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the...

Apr 02, 2012, 02:09 ET

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV

 ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III...

Jan 25, 2012, 08:00 ET

Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions

 Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced results from two studies published online today in...

Aug 04, 2011, 08:00 ET

Head Lice Returns to School: Five Tips to Avoid Panic and Worry

It's back-to-school season and for many families, that means new morning routines, homework and head lice. To view the multimedia assets...

May 09, 2011, 08:00 ET
Apr 07, 2011, 08:00 ET

Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™...

Feb 03, 2011, 03:00 ET

Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new...